Beyond the Scale: 6 in 10 Indians Face Obesity-Related Illnesses as GLP-1 “Game-Changer” Drugs Enter Market

January 25, 2026

NEW DELHI — India is facing a silent but accelerating public health crisis as a new comprehensive survey reveals that 60% of the nation’s population is currently battling complications linked to obesity, including heart disease and hormonal disorders. This data arrives at a pivotal moment for Indian healthcare; following the 2025 rollout of blockbuster GLP-1 receptor agonists like Wegovy and Mounjaro, medical experts are now weighing the potential of these “miracle” drugs against the deep-seated cultural and economic barriers to treating obesity as a chronic disease.

A Crisis of Perception: Is Obesity a Disease?

Despite the staggering prevalence of weight-related illness, a recent survey conducted by The Times of India in collaboration with Novo Nordisk highlights a significant “awareness gap.” Out of 16,741 respondents, only 53% view obesity as a legitimate medical condition. Approximately 32% dismiss it as a lifestyle choice or a non-issue, while 15% remain unsure.

This lack of medical recognition persists even though the struggle to manage weight is nearly universal. The survey found that over 80% of respondents have made “sincere efforts” to lose weight, yet many remain stuck in a cycle of temporary loss and regain.

“Obesity is not a failure of willpower; it is a chronic, relapsing disease,” says the World Health Organization (WHO), which estimates that over 1 billion people globally are living with the condition. In India, the National Family Health Survey (NFHS-5) confirms that nearly one in four adults is now overweight or obese, a figure that is rising rapidly in both urban centers and rural villages.

The Indian Context: Abdominal Obesity and Rising Risks

While the global conversation often focuses on Body Mass Index (BMI), research published in The Lancet Regional Health – Southeast Asia suggests that for Indians, the danger is often hidden around the midsection.

The study found that abdominal obesity—fat stored around vital organs—affects 40% of women and 12% of men in India. Most alarmingly, 50-60% of women between the ages of 30 and 49 fall into this high-risk category. While once considered a “disease of the affluent,” obesity is now penetrating lower and middle socioeconomic sections, driven by the increased availability of ultra-processed foods and sedentary lifestyles.

Enter the GLP-1 Revolution: Ozempic, Wegovy, and Mounjaro

To combat this epidemic, the Indian medical landscape underwent a seismic shift in 2025 with the official launch of three major GLP-1 receptor agonists (RAs):

• Mounjaro (Tirzepatide): Launched March 2025

• Wegovy (Semaglutide): Launched June 2025

• Ozempic (Semaglutide): Launched December 2025

How These Drugs Work

GLP-1 RAs mimic a natural hormone called Glucagon-Like Peptide-1. When we eat, this hormone is released to tell the brain we are full. For many living with obesity, this signaling pathway is impaired.

These medications target the hypothalamus—the brain’s appetite control center—to:

1. Increase Satiety: Patients feel full faster and stay full longer.

2. Slow Gastric Emptying: Food stays in the stomach longer, preventing sharp blood sugar spikes.

3. Regulate Insulin: They improve the body’s ability to process glucose, making them effective for both Type 2 diabetes and chronic weight management.

Clinical data suggests these drugs can facilitate a sustained weight loss of 5% to 15%, and in some cases even higher, which far outperforms traditional diet and exercise alone.

The “5% Threshold”: Why Small Losses Matter

For a patient weighing 100kg, losing just 5kg (5%) can be life-changing. Medical experts emphasize that “managing obesity” is about metabolic health, not aesthetics.

Expert Commentary: Not a “Magic Bullet”

While the excitement surrounding GLP-1s is palpable, healthcare providers urge caution. “Only 16% of Indians are well-informed about prescription options for obesity,” the TOI survey noted. This lack of information can lead to misuse or unrealistic expectations.

“These are powerful medical tools, not a ‘get out of gym free’ card,” says Dr. Arvinder Singh, a metabolic specialist not involved in the survey. “The best results are seen when these medications are paired with structured nutritional counseling and physical activity. Furthermore, these are often long-term treatments; when patients stop the medication without lifestyle foundations, the weight frequently returns.”

Potential Limitations

• Cost and Access: Despite their launch, the price point of these branded medications remains high for the average Indian household.

• Side Effects: Common issues include nausea, vomiting, and diarrhea, particularly during the initial dose-escalation phase.

• Muscle Loss: Rapid weight loss can lead to a decrease in lean muscle mass if not accompanied by protein-rich diets and resistance training.

The Path Forward

The surge in obesity-related complications in India—affecting 6 in 10 people—is a wake-up call for the nation’s healthcare infrastructure. The arrival of GLP-1 drugs offers a potent new weapon, but the survey results suggest that the first step isn’t a prescription—it’s a shift in mindset.

Treating obesity as a chronic medical condition rather than a personal failing may be the key to unlocking the full potential of these new therapies.

References

1. https://www.ndtv.com/health/6-in-10-indians-suffering-from-obesity-related-problems-new-survey-says-glp-1-drugs-to-play-role-in-treatment-10877635

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.